Atbtherapeutics (BE)

https://www.atbtherapeutics.com

LinkedIn: https://www.linkedin.com/company/atbtherapeutics

atbtherapeutics aims to generate a pipeline of novel biologics for hard-to-treat hematological and solid cancers. The company’s proprietary and versatile plant-based atbiofarm technology enables the production of its antibody-toxin bioengineered molecules, called atbodies, to be designed for targeted monoclonal antibody therapy with very high efficacy as well as unprecedented safety. The atbody fusion proteins recombinantly manufactured in a single-step process are composed of a full-length antibody, a peptide linker and a toxic peptide payload. The unique composition of the atbody format, avoiding chemical linker issues, generates increased potency, stability and superior targeted exposure and can potentially reduce the therapeutic dose needed without compromising efficacy. The novel mechanism of action of atbody product candidates has the potential to evade major mechanisms of cancer cell resistance, providing a promising therapeutic solution for hard-to-treat and refractory tumors. *

	Start	2018-01-01 established (s-off)
	Industry	antibody-drug conjugates (ADC) technology
	Industry 2	recombinant protein production in plant cells
	Person	Magy, Bertrand (Atbtherapeutics 202010 CEO)
	Person 2	Vandeput, Philippe (Atbherapeutics 202110– CBO before UCB + Baxter + Novartis/Sandoz)

	Region	Belgium_oo
	Country	Belgium
	Street	8 Rue de la Science Novalis Science Park
	City	6900 Aye
		Address record changed: 2024-01-05

Basic data	Employees	n. a.

		* Document for »About Section«: Atbtherapeutics. (10/5/21). "Press Release: Atbtherapeutics Expands Leadership Team and Scientific Advisory Board with Pharmaceutical Industry Experts". Aye.

		Record changed: 2024-02-12